Archynetys Live news trend intelligence
▲ Peaking Business 🔮 Archynetys predicts: fades by tomorrow

Pharma Company And Drug Testing Industry Claim Trump's Rescheduling Move Will 'Increase Marijuana Abuse'

Pharmaceutical companies and drug testing industry push back against Trump's marijuana rescheduling move

4sources
5articles
3velocity
+0%since first seen
2h agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

The pharmaceutical industry and drug testing companies are criticizing President Trump's decision to reschedule marijuana. They argue that the move will lead to increased marijuana abuse. Coverage emphasizes the potential impact on the cannabis industry and the regulatory environment.

The Motley Fool, Marijuana Moment, and MJBizDaily are among the outlets reporting on the topic. Business of Cannabis highlights the DEA rescheduling hearing, noting that a witness conceded regulation reduces crime. What to watch next: The cannabis industry's response to the rescheduling move.

The involvement of marijuana companies in legal challenges. The potential regulatory changes and their impact on crime rates.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 2h ago.

Quick answers

What is the pharmaceutical industry's stance on Trump's marijuana rescheduling?

The pharmaceutical industry claims that Trump's rescheduling move will increase marijuana abuse.

Which outlets are covering the cannabis industry's response to the rescheduling?

The Motley Fool, Marijuana Moment, and MJBizDaily are among the outlets reporting on the topic.

What was discussed during the DEA rescheduling hearing?

According to coverage from Business of Cannabis, a witness conceded that regulation reduces crime.

Coverage (5)

Topics

Related trends